About NBR“Nightly Business Report produced by CNBC” (NBR) is an award-winning and highly-respected nightly business news program that airs on public television. Television’s longest-running evening business news broadcast, “NBR” features in-depth coverage and analysis of the biggest financial news stories of the day and access to some of the world’s top business leaders and policy makers.
- Pfizer CEO: This is what Trump doesn’t understand about the pharma industry
- After hours buzz: CSX, UAL, GIMO & more
- Google was overwhelmingly against Trump, now it's trying to win him over
- Former Apple engineer: Tim Cook made Apple a 'boring operations company'
- 52% of Americans disapprove of Trump's preparations for the Oval Office, says NBC-WSJ poll
NBR on TwitterMy Tweets
Subscribe to RSS
Biotech & Pharmaceuticals
More than $125 million has been spent over an initiative to bar state agencies from paying more for drugs than the Veterans Affairs Department pays.
Price increases on life-saving EpiPens have parents outraged — but the CEO of the company that makes them said no one’s more frustrated than her.
With biotech stocks at their highest level since January, one strategist thinks a Donald Trump presidential win could send them even higher.
Biotech has been at a low year-to-date, but traders believe the sector is going to make a comeback.
Meg Tirrell explains what to look for in the biotech industry in 2016.
One morning in October, I was frantically scrambling around my apartment, trying to find a thumb drive. It’s probably the most valuable thumb drive I’ll ever have, and I couldn’t believe I had misplaced it. It contains the blueprint of who I am: My genome. Or at least, all the ways my genes differ from …
Meg Tirrell reports from the American Society of Hematology’s annual meeting where many of the latest blood disease treatments were presented.
There may be a big advantage to treating people with personalized medicine — drugs and treatments tailored to an individual’s genetic profile — but improved health outcomes for them will come at a big cost. That’s because it is very costly to screen patients for such tailored treatments and to produce medicine that targets individuals …
Of the 41 new drugs that were FDA-approved in 2014, 18 were for drugs with orphan indications, a record level.
Pfizer and Allergan are combining in a $160 billion deal, handing Pfizer a new address and creating a lot of controversy.
Over the next couple of weeks two drugs that combat a rare and fatal form of muscular dystrophy will come under review, in what could be a watershed moment for patients.
Why one lawsuit accuses a drug company of illegally driving sales of its pain killing drug.
Insys Therapeutics CEO Michael Babich has stepped down, with company chairman Dr. John Kapoor taking over as CEO. The news comes as the company reported third quarter earnings on Thursday, and shortly after CNBC released an investigative piece on Wednesday on the company, which included allegations of fraud, kickbacks, and aggressive drug marketing behavior by …
The United States’ opiate drug problem isn’t limited to illegal narcotics. The sale of dangerously addictive painkillers willfully prescribed by our physicians has quadrupled in the past decade, and one company in particular is pushing pain to the legal edge of aggressive medical marketing. According to criminal complaints, attorney generals’ reports and CNBC sources, specialty …
Valeant cuts ties with specialty pharmacy Philidor, which distributed some of its prescriptions.